RUBINSTEIN JULIE sold $998K of ADPT
RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $28.00 ($26.58–$28.90, $1.00M total) across 5 trades over 2026-10-27 to 2026-10-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The filing reveals a $998K sale by a top executive, offering a data point for traders monitoring insider sentiment.
Market read
Small‑scale insider sell; limited immediate market impact but useful for sentiment analysis.
What to watch
Potential upcoming clinical data releases or financing needs that prompted the sale.
Background
Form 4 disclosures provide transparent insight into insider trading activity.
Ticker impact
Form 4 filing shows President and COO Julie Rubinstein sold $998K of ADPT shares via a 10b5‑1 plan.
likely modest pressure as the market prices in the insider sell
The sale is relatively small ($1M) for a mid‑cap biotech, but it is a direct insider transaction disclosed for the first time.
Market effects
Minimal impact on the broader biotech sector; insider sales are routine.
None
None
Counterpoint
The sale could be a routine liquidity move unrelated to company fundamentals.
Key entities
- ExecutiveJulie Rubinstein
President and COO of Adaptive Biotechnologies
- CompanyAdaptive Biotechnologies Corp
US‑listed biotech (ticker ADPT)



